Trial site
Cotton O'Neil Digestive Health Center
Topeka, Kansas 66606, United StatesNot linked to an institution yet
- 9running trials
- 1closed trial
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 24 trials
- Phase 2/31 trial
- Status
- Active, not recruiting6 trials
- Recruiting3 trials
- Completed1 trial
- Lead sponsor
- Janssen Research & Development, LLC6 trials
- Eli Lilly and Company4 trials
Running trials
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073· Phase 2· Eli Lilly and Company· Source
Contact: Curtis Baum (principal investigator)
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099· Phase 2· Eli Lilly and Company· Source
Contact: Curtis Baum (principal investigator)
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Curtis Baum (principal investigator)
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error